RxDoctor Payments DataLook up a doctor →

Tamer Yacoub, MD

Endocrinology, Diabetes & Metabolism · Fall River, MANPI 1578557807

Payments from drug & device makers

$1,430,845in general payments, 2019–2025

Across 1,593 payments — averaging $898.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$594K
  • Novo Nordisk$249K
  • Lilly USA, LLC$214K
  • Corcept Therapeutics$75K
  • Bayer$39K
  • AbbVie$37K
  • plus $224K from 54 others
$40,199in research payments, 2019–2025

Across 10 payments — averaging $4019.94 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$40K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Eli Lilly30$593,522
Novo Nordisk341$248,534
Lilly USA, LLC334$214,360
Corcept Therapeutics97$74,929
Bayer64$38,846
AbbVie37$36,625
Abbott103$32,767
Ascendis Pharma Endocrinology Inc29$32,487
Boehringer Ingelheim68$27,666
Amryt Pharma Holdings Ltd26$27,265
Esperion Therapeutics, Inc.51$16,603
Xeris Pharmaceuticals, Inc.51$15,605
Aegerion Pharmaceuticals, Inc.25$14,837
Merck23$10,803
F. Hoffmann-la Roche AG2$10,793
Sanofi-aventis U.S. LLC26$9,280
Johnson & Johnson13$7,431
Genentech, Inc.2$5,205
Ascensia Diabetes Care US Inc.7$4,017
Amgen(2 entities)70$1,732
AstraZeneca(2 entities)37$1,689
Sanofi US Services Inc.1$955
Zealand Pharma US, Inc.1$750
Amarin Pharma, Inc.32$642
Mannkind Corporation20$606
Cequr Corporation2$359
Kyowa Kirin, Inc.10$336
Tandem Diabetes Care, Inc.6$191
Dexcom, Inc.9$188
Sequel Med Tech, LLC3$164
Novartis10$161
Lexicon Pharmaceuticals, Inc.4$110
GSK2$110
Amneal Pharmaceuticals LLC5$105
Inari Medical, Inc.1$101
Medtronic5$98
Antares Pharma, Inc.4$86
Regeneron Healthcare Solutions, Inc.3$75
Insulet Corporation3$74
Madrigal Pharmaceuticals3$73
Lifescan, Inc.3$56
Neurocrine Biosciences, Inc.2$54
Ipsen Biopharmaceuticals, Inc3$50
Pfizer2$46
Currax Pharmaceuticals LLC3$45
Kowa Pharmaceuticals America, Inc.3$44
Chiesi USA, Inc.2$44
Radius Health, Inc.1$40
Shire North American Group Inc2$37
Recordati_rare_diseases_inc.1$33
Nevro Corp.1$32
IBSA Pharma Inc.2$32
Alnylam Pharmaceuticals Inc.1$27
RGH Enterprises LLC1$25
Tolmar, Inc.1$24
Valeritas, Inc.1$21
Lucid Diagnostics Inc.1$17
Ultragenyx Pharmaceutical Inc.1$17
Vifor Pharma, Inc.1$13
Janssen Scientific Affairs, LLC1$13

How this compares

$1,430,845 in reported general payments places this provider in the 95th percentile of 360 endocrinology, diabetes & metabolism providers in Massachusetts.

See all endocrinology, diabetes & metabolism providers in Massachusetts →

Medicare billing

Part B allowed, 2024
$375,872
Medicare patients
984
Services billed
12,782

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Fall River

See the full list for Massachusetts →

Where these figures come from

Is this you, or does something look wrong? →